In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 23 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

3-year follow-up results of heart failure patients included in the Journey HF-TR study

Session HFA Discoveries - ePosters

Speaker Cengiz Sabanoglu

Event : HFA Discoveries 2020

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Pathophysiology
  • Session type : ePoster

Authors : C Sabanoglu (Ankara,TR), B Ozbay (Izmir,TR), U Kocabas (Manisa,TR), G Gok (Mardin,TR), A Coner (Alanya,TR), L Bekar (Çorum,TR), E Gazi (Canakkale,TR), M Cengiz (Istanbul,TR), E Yildirim (Elazig,TR), H A Cakmak (Bursa,TR), A R Demir (Istanbul,TR), S Kilic (Gaziantep,TR), UY Sinan (Istanbul,TR), MK Akboga (Ankara,TR), M Zoghi (Izmir,TR)

Authors:
C Sabanoglu1 , B Ozbay2 , U Kocabas3 , G Gok4 , A Coner5 , L Bekar6 , E Gazi7 , M Cengiz8 , E Yildirim9 , H A Cakmak10 , A R Demir11 , S Kilic12 , UY Sinan13 , MK Akboga14 , M Zoghi2 , 1Turkiye Yuksek Ihtisas Hospital - Ankara - Turkey , 2Ege University, Cardiology - Izmir - Turkey , 3Soma State Hospital, Cardiology - Manisa - Turkey , 4Mardin State Hospital, Cardiology - Mardin - Turkey , 5Baskent University, Alanya Hospital, Cardiology - Alanya - Turkey , 6Hitit University, School of Medicine, Cardiology - Çorum - Turkey , 7Canakkale 18 March University, Cardiology - Canakkale - Turkey , 8Istanbul University-Cerrahpasa Institute of Cardiology - Istanbul - Turkey , 9Firat University, Cardiology - Elazig - Turkey , 10Mustafa Kemal State Hospital, Cardiology - Bursa - Turkey , 11Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Cardiology - Istanbul - Turkey , 12Nizip State Hospital, Cardiology - Gaziantep - Turkey , 13Istanbul University Cardiology Institute - Istanbul - Turkey , 14Gazi University, Cardiology - Ankara - Turkey ,

Citation:

Background: Heart failure is a disease with a high incidence of morbidity and mortality all over the world. For these reasons, the pathophysiology, diagnosis, follow-up and treatment options of heart failure have been frequently investigated recently. When the studies conducted in our country are examined, there are a limited number of studies conducted for this purpose.
Purpose: In this study, we aimed to examine the 3-year follow-up results of heart failure cases in the Journey HF-TR study previously conducted with the real life data of our country.
Methods: The retrospective study included the 1311cases in the Journey HF-TR study, which was followed up regularly for 3 years. During the 3-year follow-up period, hospitalization, medications used, mortality, and the cardiovascular events (myocardial infarction, stroke, embolism, revascularization) were recorded regularly.
Results: During follow-up, 930 (70.9%) of the patients were hospitalized. The mortality rate was 52.1% (n: 683) in the entire population. In the follow-up period, a total of 219 (16.7%) cardiovascular events developed in the entire population. Myocardial infarction occurred in 9.5% of cases, stroke in 3.6%, and embolism in 1.1%. Revascularization was performed in 7.6% of the cases, device implantation in 4.7% and heart transplantation in 0.4%. Having a cardiovascular event was found to increase the mortality risk by 1.75 times (HR:1.75; p< 0.001). Device implantation was determined to reduce the mortality risk by 1.53 times (1 / 0.65) (HR:0.65; p=0.037). Drugs that reduce the risk of mortality were determined as renin angiotensin system blocker (HR:0.73; p<0.001), beta blocker (HR:0.68; p<0.001) and valsartan-sacubitril (HR:0.18; p=0.015). The presence of hospitalazation was found to increase the mortality risk by 28.78 times (HR:28.78; p<0.001).
Conclusion: Mortality developed in approximately one fourth of the patients as a result of 3-year follow-up. The rates of cardiovascular events developing in our study population were similar to international studies. However, hospitalization rates and mortality risk of hospitalization were slightly higher.

This content is currently on FREE ACCESS, enjoy another 23 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are